Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review

Journal of the Neurological Sciences

Volumn 355, Issue 1-2, 2015, Pages 7-17

  De Carvalho Jennings Pereira, Wildéa Lice ^a   Reiche, Edna Maria Vissoci ^a   Kallaur, Ana Paula ^a   Kaimen Maciel, Damacio Ramón ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Aquaporin 4 antibodies; Autoimmunity; Cytotoxicity; Neuromyelitis optica; Optic nerve; Spinal cord

Indexed keywords

AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CORTICOSTEROID; GLUTAMIC ACID; HLA ANTIGEN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; ANTIBODY; AQUAPORIN 4;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL FEATURE; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; CORTICOSTEROID THERAPY; EFFECTOR CELL; ENVIRONMENTAL FACTOR; ETHNICITY; EXCITOTOXICITY; HEREDITY; HLA SYSTEM; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; BLOOD; IMMUNOLOGY; NEUROMYELITIS OPTICA; OPTIC NERVE; PATHOLOGY; SPINAL CORD;

ANTIBODIES; AQUAPORIN 4; HUMANS; NEUROMYELITIS OPTICA; OPTIC NERVE; SPINAL CORD;

EID: 84937523914     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2015.05.034     Document Type: Review

References (136)

1. A. Jacob, M. Matiello, D.M. Wingerchuk, C.F. Lucchinetti, S.J. Pittock, and B.G. Weinshenker Neuromyelitis optica: changing concepts J. Neuroimmunol. 187 2007 126 138
2. M. Matiello, A. Jacob, D. Wingerchuk, and B.G. Weinshenker Neuromyelitis optica Curr. Opin. Neurol. 20 2007 255 260
3. W. Kim, S.H. Kim, and H.J. Kim New insights into neuromyelitis optica J. Clin. Neurol. 7 2011 115 127
4. S. Jarius, and B. Wildemann The history of neuromyelitis optica J. Neuroinflammation 10 2013 8 10.1186/1742-2094-10-8
5. S. Matà, and F. Lolli Neuromyelitis optica: An update J. Neurol. Sci. 303 2011 13 21
6. R.N. Mandler Neuromyelitis optica - Devic's syndrome, update Autoimmun. Rev. 5 2006 537 543
7. M.C. Papadopoulos, J.I. Bennett, and A.S. Verkman Treatment of neuromyelitis optica: state-of-the-art and emerging therapies Nat. Rev. Neurol. 2014 10.1038/nrneurol.2014.141
8. J.F. Rivera, J.F. Kurtzke, V.J.A. Booth, and V.T. Corona V Characteristics of Devic's disease (neuromyelitis optica) in Mexico J. Neurol. 255 2008 710 715
9. D.M. Wingerchuk Neuromyelitis optica: effect of gender J. Neurol. Sci. 286 2009 13 18
10. M.A. Mealy, D.M. Wingerchuk, B.M. Greenberg, and M. Levy Epidemiology of Neuromyelitis optica in the United States: a multicenter analysis Arch. Neurol. 69 2012 1176 1180
11. M. Cossburn, G. Tackley, K. Baker, G. Ingram, M. Burtonwood, G. Malik, T. Pickersgill, J. Te Water Naude, and N. Robertson The prevalence of neuromyelitis optica in South East Wales Eur. J. Neurol. 19 2012 655 659
12. M.A. Lana-Peixoto Devic's neuromyelitis optica: a critical review Arq. Neuropsiquiatr. 66 2008 120 138
13. M.A. Mealy, D.M. Wingerchuk, B.M. Greenberg, and M. Levy Epidemiology of neuromyelitis optica in the United States: a multicenter analysis Arch. Neurol. 69 2012 1176 1180
14. M. Cossburn, G. Tackley, K. Baker, G. Ingram, M. Burtonwood, G. Malik, and et al. The prevalence of neuromyelitis optica in South East Wales Eur. J. Neurol. 19 2012 655 659
15. J.A. Cabrera-Gómez, J.F. Kurtzke, A. González-Quevedo, and R. Lara-Rodríguez An epidemiological study of neuromyelitis optica in Cuba J. Neurol. 256 2009 35 44
16. N. Asgari, S.T. LIllevang, H.P. Skejoe, M. Falah, E. Stenager, and K.O. Kyvik A population-based study of neuromyelitis optica in Caucasians Neurology 76 2011 1589 1595
17. M.A. Sahraian, Z. Moinfar, S. Khorramnia, and M.M. Ebrahim Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients Eur. J. Neurol. 17 2010 794 799
18. R.M. Papais-Alvarenga, C.M. Miranda-Santos, M. Puccioni-Sohler, A.M. De Almeida, S. Oliveira, C.A. Basilio de Oliveira, and et al. Optic neuromyelitis syndrome in Brazilian patients J. Neurol. Neurosurg. Psychiatry 73 2002 429 435
19. P. Huppke, M. Blüthner, O. Bauer, W. Stark, K. Reinhardt, B. Huppke, and et al. Neuromyelitis optica and NMO-IgG in European pediatric patients Neurology 75 2010 1740 1744 (http://www.ncbi.nlm.nih.gov/pubmed?term=G%C3%A4rtner%20J%5BAuthor%5D&cauthor=true&cauthor-uid=21060098)
20. D.M. Wingerchuk, V.A. Lennon, S.J. Pittock, C.F. Lucchinetti, and B.G. Weinshenker Revised diagnostic criteria for neuromyelitis optica Neurology 66 2006 1485 1489
21. K. Fujihara, T. Misu, I. Nakashima, T. Takahashi, M. Bradl, H. Lassmann, and et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease Clin. Exp. Neuroimmunol. 3 2012 58 73
22. M.A. Lana-Peixoto, and D. Callegaro The expanded spectrum of neuromyelitis optica - evidences for a new definition Arq. Neuropsiquiatr. 70 10 2012 807 813
23. B.G. Weinshenker Clinical spectrum of neuromyelitis optica 2013 Neurol. Clin. Neurosci. 2 2014 23 27 10.1111/ncn3.79
24. A. Iyer, L. Elsone, R. Appleton, and A. Jacob A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica Autoimmunity 47 2014 154 161
25. P. Sergio, B. Mariana, O. Alberto, U. Claudia, R. Oscar, M. Pablo, and et al. Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature Clin. Rheumatol. 29 2010 1335 1338 (http://www.ncbi.nlm.nih.gov/pubmed?term=Alberto%20A%5BAuthor%5D&cauthor=true&cauthor-uid=20535509)
26. K. Fujihara Neuromyelitis optica and astrocytic damage in its pathogenesis J. Neurol. Sci. 306 2011 183 187
27. M.I. Leite, E. Coutinho, M. Lana-Peixoto, S. Apostolos, P. Waters, D. Sato, and et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients Neurology 78 2012 1601 1607
28. K. Maruta, Y. Sonoda, Y. Uchida, T. Takahashi, and H. Fukunaga A case of neuromyelitis optica associated with anti-aquaporin 4 antibody and other autoantibodies Nihon Ronen Igakkai Zasshi 49 4 2012 491 495
29. D.M. Wingerchuk, and B.G. Weinshenker The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease Mult. Scler. 18 2012 5 10
30. E. Freitas, and J. Guimarães Neuromyelitis optica spectrum disorders associated with other autoimmune diseases Rheumatol. Int. 2014 10.1007/s00296-014-3066-3
31. S. Jarius, F. Paul, D. Franciotta, J. De Seze, C. Münch, M. Salvetti, and et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature Mult. Scler. 18 2012 1135 1143
32. D.K. Sato, M. Lana-Peixoto, K. Fujihara, and J. De Seze Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status Brain Pathol. 23 2013 647 660
33. J. Sellner, B. Hemmer, and M. Mühlau The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes J. Autoimmun. 34 2010 371 379
34. H. Wang, Y. Dai, W. Qiu, X. Zhong, A. Wu, Y. Wang, and et al. HLA-DPB1∗0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese J. Neuroimmunol. 233 2011 181 184
35. Y. Blanco, G. Ercilla-González, S. Llufriu, B. Casanova-Estruch, M.J. Magraner, L. Ramió-Torrentá, and et al. HLA-DRB1 typing in Caucasians patients with neuromyelitis optica Rev. Neurol. 53 3 2011 146 152
36. R. Deschamps, L. Paturel, S. Jeannin, N. Chausson, S. Olindo, O. Béra, and et al. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population Mult. Scler. 17 2011 24 31
37. D.G. Brum, A.A. Barreira, A.C. Dos Santos, D.R. Kaimen-Maciel, M. Matiello, R.M. Costa, and et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis Mult. Scler. 16 2010 21 29
38. H. Zephir, I. Fajardy, O. Outteryck, F. Blanc, N. Roger, M. Fleury, and et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult. Scler. 15 2009 571 579
39. M. Matiello, H.J. Kim, W. Kim, D.G. Brum, A.A. Barreira, D.J. Kingsbury, and et al. Familial neuromyelitis optica Neurology 75 2010 310 315
40. S. Namgoong, J.S. Bae, H.S. Cheong, J.H. Kim, J.Y. Kim, L.H. Kim, and et al. No association between CCL2 gene polymorphisms and risk of inflammatory demyelinating diseases in a Korean population Tissue Antigens 84 2014 223 228
41. A. Szczucinski, and J. Losy Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies Acta Neurol. Scand. 115 2007 137 146
42. R.M. Ransohoff The chemokine system in neuroinflammation: an update J. Infect. Dis. 186 Suppl. 2 2002 152 156
43. T.L. Sorensen, and F. Sellebjerg Distinct chemokine receptor and cytokine expression profile in secondary progressive MS Neurology 57 2001 1371 1376
44. O. Bruserud, and A.O. Kittang The chemokine system in experimental and clinical hematology Curr. Top. Microbiol. Immunol. 341 2010 3 12
45. P. Van Der Voorn, J. Tekstra, R.H. Beelen, C.P. Tensen, P. Van Der Valk, and C.J. De Groot Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions Am. J. Pathol. 154 1999 45 51
46. D.J. Mahad, and R.M. Ransohoff The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE) Semin. Immunol. 15 2003 23 32
47. I.F. Charo, and R.M. Ransohoff The many roles of chemokines and chemokine receptors in inflammation N. Engl. J. Med. 354 2006 610 621
48. A. Kroner, M. Mäurer, S. Loserth, C. Kleinschnitz, B. Hemmer, B. Rosche, and et al. Analysis of the monocyte chemoattractant protein 1-2518 promoter polymorphism in patients with multiple sclerosis Tissue Antigens 64 2004 70 73
49. A. Messadi, N. Fekih-Mrissa, A. Kallel, C. Bouguerra, Y. Sediri, J. Zaweli, and et al. Lack of association between monocyte protein-1 (MCP-1)-2518 A>G chemoattractant and C-C chemokine receptor 2 (CCR2) Val64Ile polymorphisms and multiple sclerosis in a Tunisian population J. Clin. Neurosci. 17 2010 1311 1313
50. S. Hou, P. Yang, L. Xie, L. Du, H. Zhou, and Z. Jiang Monocyte chemoattractant protein (MCP)-1-2518 A/G SNP in Chinese Han patients with VKH syndrome Mol. Vis. 15 2009 1537 1541
51. M.F. González-Escribano, B. Torres, F. Aguilar, R. Rodríguez, A. García, A. Valenzuela, and et al. MCP-1 promoter polymorphism in Spanish patients with rheumatoid arthritis Hum. Immunol. 64 2003 741 744
52. H.J. Kim, H.Y. Park, E. Kim, K.S. Lee, K.K. Kim, B.O. Choi, and et al. Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica Neurobiol. Dis. 37 2010 349 355
53. T.J. Park, H.J. Kim, J.H. Kim, J.S. Bae, H.S. Cheong, B.L. Park, and et al. Associations of CD6, TNFRSF1A, and IRF8 polymorphisms with risk of inflammatory demyelinating diseases Neuropathol. Appl. Neurobiol. 39 2013 519 530
54. J.A. Barbosa, S.J. Mentzer, M.E. Kamarck, J. Hart, P.A. Biro, J.L. Strominger, and et al. Gene mapping and somatic cell hybrid analysis of the role of human lymphocyte function-associated antigen-3 (LFA-3) in CTL-target cell interactions J. Immunol. 136 1986 3085 3091
55. D.A. Hafler, A. Compston, S. Sawcer, E.S. Lander, M.J. Daly, P.L. De Jager, and et al. Risk alleles for multiple sclerosis identified by a genomewide study N. Engl. J. Med. 357 2007 851 862
56. J.Y. Kim, J.S. Bae, H.J. Kim, and H.D. Shin CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population BMC Neurol. 14 2014 57
57. H. Wang, X. Zhong, K. Wang, W. Qiu, J. Li, Y. Dai, and et al. Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese - a case control study J. Neurol. Sci. 314 2012 26 28
58. M. Kawaguchi, D. Takahashi, N. Hizawa, S. Suzuki, S. Matsukura, F. Kokubu, and et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity J. Allergy Clin. Immunol. 117 2006 795 801
59. T. Arisawa, T. Tahara, T. Shibata, M. Nagasaka, M. Nakamura, Y. Kamiya, and et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis J. Clin. Immunol. 28 2008 44 49
60. G.B. Nordang, M.K. Viken, J.E. Hollis-Moffatt, T.R. Merriman, O.T. Førre, K. Helgetveit, and et al. Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand Rheumatology (Oxford) 48 2009 367 370
61. A.M. De Sousa, M. Puccioni-Sohler, A.D. Borges, L. Fernandes Adorno, M. Papais Alvarenga, and R.M. Papais Alvarenga Post-dengue neuromyelitis optica: case report of a Japanese-descendent Brazilian child J. Infect. Chemother. 12 2006 396 398
62. S. Olindo, M. Bonnan, H. Merle, A. Signate, D. Smadja, and P. Cabre Neuromyelitis optica associated with subacute human T-lymphotropic virus type 1 infection J. Clin. Neurosci. 17 2010 1449 1451
63. D.G. Brum, E.A. Donadi, A.C. Dos Santos, O.M. Takayanagui, W.J.R. Marques, and A.A. Barreira Seropositive antiaquaporin-4 antibody associated with multisegmental myelitis in a patient with paracoccidioidomycosis J. Neurol. Sci. 309 2011 151 153
64. V. Zatjirua, J. Butler, J. Carr, and F. Henning Neuromyelitis optica and pulmonary tuberculosis: a case-control study Int. J. Tuberc. Lung Dis. 15 2011 1675 1680
65. A.M. Feyissa, P. Singh, and R.G. Smith Neuromyelitis optica in patients with coexisting human immunodeficiency virus infections Mult. Scler. 19 2013 1363 1366
66. H. Zhang, and A.S. Verkman Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica J. Clin. Invest. 123 2013 2306 2316
67. C.F. Lucchinetti, R.N. Mandler, D. McGavern, W. Bruck, G. Gleich, R.M. Ransohoff, and et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica Brain 125 2002 1450 1461
68. S. Saadoun, P. Waters, B.A. Bell, A. Vincent, A.S. Verkman, and M.C. Papadopoulos Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice Brain 133 2010 349 361
69. D.M. Wingerchuk, V.A. Lennon, C.F. LucchinettI, S.J. Pittock, and B.G. Weinshenker The spectrum of neuromyelitis optica Lancet Neurol. 6 2007 805 815
70. M.C. Papadopoulos, and A.S. Verkman Aquaporin 4 and neuromyelitis optica Lancet Neurol. 11 2012 525 544
71. A. Uzawa, M. Mori, S. Sawai, S. Masuda, M. Muto, T. Uchida, and et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optics attacks Clin. Chim. Acta 421 2013 181 183
72. M. Storoni, A. Petzold, and G.T. Plant The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis PLoS ONE 6 2011 e23489 10.1371/journal.pone.0023489
73. J.S. Tzartos, C. Stergiou, K. Kilidireas, P. Zisimopoulou, T. Thomaidis, and S.J. Tzartos Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders PLoS One 8 2013 e74773 10.1371/journal.pone.0074773
74. P. Waters, and A. Vincent Detection of anti-aquaporin-4 antibodies in Neuromyelitis optica: current status of the assays Int. MS J. 15 2008 99 105
75. C. González, J.M. González-Buitrago, and G. Izquierdo Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica Clin. Chim. Acta 415 2012 350 360
76. M. Bonnan, and P. Cabre Plasma exchange in severe attacks of neuromyelitis optica Mult. Scler. Int. 2012 2012 10.1155/2012/787630
77. V.A. Lennon, D.M. Wingerchuk, T.J. Kryzer, S.J. Pittock, C.F. Lucchinetti, K. Fujihara, and et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis Lancet 364 2004 2106 2112
78. T. Adoni, A.M. Lino, P.E. Marchiori, F. Kok, and D. Callegaro Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica Arq. Neuropsiquiatr. 66 2008 295 297
79. M. Matiello, V.A. Lennon, A. Jacob, S.J. Pittock, C.F. Lucchinetti, D.M. Wingerchuk, and et al. NMO-IgG predicts the outcome of recurrent optic neuritis Neurology 70 2008 2197 2200
80. G. Akman-Demir, E. Tüzün, P. Waters, S. Içöz, M. Kürtüncü, S. Jarius, and et al. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients J. Neurol. 258 2011 464 470
81. A. Dellavance, R.R. Alvarenga, S.H. Rodrigues, F. Kok, A.W. De Souza, and L.E. Andrade Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases Eur. J. Neurol. 19 2012 248 252
82. P.J. Waters, A. McKeon, M.I. Leite, S. Rajasekharan, V.A. Lennon, A. Villalobos, and et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays Neurology 78 2012 665 671
83. F. Di Pauli, S. Mader, K. Rostasy, K. Schanda, B. Bajer-Kornek, R. Ehling, and et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases Clin. Immunol. 138 2011 247 254
84. S. Mader, V. Gredler, K. Schanda, K. Rostasy, I. Dujmovic, K. Pfaller, and et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders J. Neuroinflammation 8 2011 1 14
85. S. Saadoun, P. Waters, G.P. Owens, J.L. Bennett, A. Vincent, and M.C. Papadopoulos Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain Acta Neuropathol. Commun. 2 2014 1 9
86. J. Kitley, M. Woodhall, P. Waters, M.I. Leite, E. Devenney, J. Craig, and et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype Neurology 79 2012 1273 1277
87. D. Sato, D. Callegaro, M. Lana-Peixoto, P.J. Waters, F.M. De Haidar Jorge, and et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders Neurology 82 2014 1 8
88. M. Mitsdoerffer, V. Kuchroo, and T. Korn Immunology of neuromyelitis optica: a T cell-B cell collaboration Ann. N. Y. Acad. Sci. 1283 2013 57 66
89. D.J. Graber, M. Levy, D. Kerr, and W.F. Wade Neuromyelitis optica pathogenesis and aquaporin 4 J. Neuroinflammation 5 2008 22 10.1186/1742-2094-5-22
90. S.R. Kalluri, V. Rothhammer, O. Staszewski, R. Srivastava, F. Petermann, M. Prinz, and et al. Functional characterization of aquaporin-4 specific T cells: towards a model for NEUROMYELITIS OPTICA PLoS One 6 1 2011 e16083 10.1371/journal.pone.0016083
91. M. Pohl, M.T. Fischer, S. Mader, K. Schanda, M. Kitic, R. Sharma, and et al. Pathogenic T cell responses against aquaporin 4 Acta Neuropathol. 122 2011 21 34
92. M. Kinoshita, and Y. Nakatsuji Where do AQP4 antibodies fit in the pathogenesis of NMO? Mult. Scler. Int. 2012 2012 862169 10.1155/2012/862169
93. Y. Li, H. Wang, Y. Long, Z. Lu, and X. Hu Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis J. Neuroimmunol. 234 2011 155 160
94. J. Goverman Autoimmune T, cell responses in the central nervous system Nat. Rev. Immunol. 9 2009 393 407
95. H.S. Domingues, M. Mues, H. Lassmann, H. Wekerle, and G. Krishnamoorthy Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis PLoS One 5 2010 e15531 10.1371/journal.pone.0015531
96. M. Bradl, T. Misu, T. Takahashi, M. Watanabe, S. Mader, M. Reindl, and et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo Ann. Neurol. 66 2009 630 643
97. H. Nakajima, T. Hosokawa, Y. Doi, T. Ikemoto, S. Ishida, F. Kimura, and et al. Interferon-β1b increases Th2 response in neuromyelitis optica Int. J. Mol. Sci. 13 2012 12213 12223
98. Y. Shimizu, K. Ota, S. Kubo, C. Kabasawa, M. Kobayashi, T. Ohashi, and et al. Association of Th1/Th2-related chemokine receptors in peripheral T cells with disease activity in patients with multiple sclerosis and neuromyelitis optica Eur. Neurol. 66 2011 91 97
99. J. Ratelade, and A.S. Verkman Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies Int. J. Biochem. Cell Biol. 44 2012 1519 1530
100. T. Vincent, P. Saikali, R. Cayrol, A.D. Roth, A. Bar-Or, A. Prat, and et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment J. Immunol. 181 2008 5730 5737
101. P.J. Capel, J.G. Van De Winkel, I.E. Van Den Herik-Oudijk, and J.S. Verbeek Heterogeneity of human IgG Fc receptors ImmunoMethods 4 1994 25 34
102. Y. Kitazawa, Y. Warabi, M. Bandoh, T. Takahashi, and S. Matsubara Elderly-onset neuromyelitis optica which developed after the diagnosis of prostate adenocarcinoma and relapsed after a 23-valent pneumococcal polysaccharide vaccination Intern. Med. 51 2012 103 107
103. S.R. Hinson, M.F. Romero, B.F. Popescu, C.F. Lucchinetti, J.P. Fryer, H. Wolburg, and et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes Proc. Natl. Acad. Sci. U. S. A. 109 2012 1245 1250
104. P.W. Phuan, J. Ratelade, A. Rossi, L. Tradtrantip, and A.S. Verkman Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays J. Biol. Chem. 287 2012 13829 13839
105. H. Zhang, J.L. Bennett, and A.S. Verkman Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms Ann. Neurol. 70 2011 943 954
106. S.R. Hinson, S.F. Roemer, C.F. Lucchinetti, J.P. Fryer, T.J. Kryzer, J.L. Chamberlain, and et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2 J. Exp. Med. 205 2008 2473 2481
107. J.D. Rothstein, S. Patel, M.R. Regan, C. Haenggeli, Y.H. Huang, D.E. Bergles, and et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression Nature 433 2005 73 77
108. J. Ratelade, J.L. Bennett, and A.S. Verkman Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica J. Biol. Chem. 286 2011 45156 45164
109. D. Sato, D. Callegaro, M. Lana-Peixoto, and K. Fujihara Brazilian committee for treatment and research in multiple sclerosis. Treatment of neuromyelitis optica: an evidence based review Arq. Neuropsiquiatr. 70 2011 59 66
110. S. Watanabe, T. Misu, I. Miyazawa, I. Nakashima, Y. Shiga, K. Fujihara, and et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis Mult. Scler. 13 2007 968 974
111. N. Muls, K. Jnaoui, H.A. Dang, A. Wauters, J. Van Snick, C.J. Sindic, and et al. Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network J. Neuroimmunol. 243 2012 73 80
112. B.O. Khatri, J. Kramer, M. Dukic, M. Palencia, and W. Verre Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica J. Clin. Apher. 27 2012 183 192
113. K.C. Wang, S.J. Wang, C.L. Lee, S.Y. Chen, and C.P. Tsai The rescue effect of plasma exchange for neuromyelitis optica J. Clin. Neurosci. 18 2011 43 46
114. M. Bonnan, R. Valentino, S. Olindo, H. Mehdaoui, D. Smadja, and P. Cabre Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder Mult. Scler. 15 2009 487 492
115. S. Jarius, F. Aboul-Enein, P. Waters, B. Kuenz, A. Hauser, T. Berger, and et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica Brain 131 2008 3072 3080
116. D.B. Bichuetti, E.M. Lobato de Oliveira, D.M. Oliveira, N. Amorin de Souza, and A.A. Gabbai Neuromyelitis optica treatment: analysis of 36 patients Arch. Neurol. 67 2010 1131 1138
117. A. Jacob, M. Matiello, B.G. Weinshenker, D.M. Wingerchuk, C. Lucchinetti, E. Shuster, and et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients Arch. Neurol. 66 2009 1128 1133
118. R.S. Ramanathan, K. Malhotra, and T. Scott Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate BMC Neurol. 14 2014 51 10.1186/1471-2377-14-51
119. A. Minagar, and W. Sheremara Treatment of Devic's disease with methotrexate and prednisone Int. J. MS Care 2 2000 39 43
120. P. Cabre, S. Olindo, R. Marignier, S. Jeannin, H. Merle, and D. Smadja Aegis of French national observatory of multiple sclerosis. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study J. Neurol. Neurosurg. Psychiatry 84 2013 511 516
121. C. Trebst, S. Jarius, A. Berthele, F. Paul, S. Schippling, B. Wildemann, and et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS) J. Neurol. 261 2014 1 16
122. D.M. Wingerchuk, and B.G. Weinshenker Neuromyelitis optica: clinical predictors of a relapsing course and survival Neurology 60 2003 848 853
123. T. Akaishi, and I. Nakashima The treatment of neuromyelitis optica: present and future perspective J. Neurol. Disord. Stroke 2 2014 1076
124. D.M. Wingerchuk Neuromyelitis optica: potential roles for intravenous immunoglobulin J. Clin. Immunol. 33 Suppl. 1 2013 33 37
125. K. Herges, B.A. De Jong, I. Kolkowitz, C. Dunn, G. Mandelbaum, R.M. Ko, and et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein Mult. Scler. 18 2012 398 408
126. K.C. Wang, C.L. Lee, S.Y. Chen, K.H. Lin, and C.P. Tsai Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica Med. Hypotheses 76 2011 820 822
127. S.J. Pittock, V.A. Lennon, A. Mckeon, J. Mandrekar, B.G. Weinshenker, C.F. Lucchinetti, and et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study Lancet Neurol. 12 2013 554 562
128. L. Tradtrantip, H. Zhang, S. Saadoun, P.W. Phuan, C. Lam, M.C. Papadopoulos, and et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica Ann. Neurol. 71 2012 314 322
129. L. Tradtrantip, H. Zhang, M.O. Anderson, S. Saadoun, P.W. Phuan, M.C. Papadopoulos, and et al. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica FASEB J. 26 2012 2197 2208
130. M.K. Slifka, R. Antia, J.K. Whitmire, and R. Ahmed Humoral immunity due to long-lived plasma cells Immunity 8 1998 363 372
131. G. Pentón-Rol, M. Cervantes-Llanos, G. Martínez-Sánchez, J.A. Cabrera-Gómez, C.M. Valenzuela-Silva, O. Ramírez-Nuñez, and et al. TNF-α and IL-10 downregulation and marked oxidative stress in neuromyelitis optica J. Inflamm. 6 2009 18 10.1186/1476-9255-6-18
132. O. Hammer CD19 as an attractive target for antibody-based therapy MAbs 4 5 2012 571 577 10.4161/MABS.21338
133. A. Davies, and P.J. Lachmann Membrane defence against complement lysis: the structure and biological properties of CD59 Immunol. Res. 12 1993 258 275
134. N. Asavapanumas, J. Ratelade, M.C. Papadopoulos, J.L. Bennett, M.H. Levin, and A.S. Verkman Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G J. Neuroinflammation 11 2014 16 10.1186/1742-2094-11-16
135. J. Fagius, J. Lundgren, and G. Oberg Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation Mult. Scler. 15 2008 229 237
136. G.G. Illei, R. Cervera, R.K. Burt, A. Doria, F. Hiepe, D. Jayne, and et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus Ann. Rheum. Dis. 70 2011 2071 2074